Valamehr Bahram
Known title: Chief R&D OfficerCIK: 0001748177
Associated companies
Transaction History
| FATE | ▼ Sell | Open Market | 43,947 | $108K | 8/4/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 28,946 | $54K | 5/20/2026 | View on chart |
| FATE | ▲ Buy | Grant | 335,000 | $0 | 1/15/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 5,190 | $6K | 1/9/2026 | View on chart |
| FATE | ▼ Sell | Open Market | 14,466 | $15K | 8/4/2025 | View on chart |
| FATE | ▼ Sell | Open Market | 8,705 | $13K | 1/10/2025 | View on chart |
| FATE | ▲ Buy | Grant | 200,000 | $0 | 7/29/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 11,271 | $49K | 1/9/2024 | View on chart |
| FATE | ▲ Buy | Option Exercise | 423 | $580 | 1/12/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 10,917 | $57K | 1/10/2023 | View on chart |
| FATE | ▲ Buy | Option Exercise | 17,158 | $47K | 7/7/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 17,158 | $519K | 7/7/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 2,000 | $10K | 7/6/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 5,842 | $16K | 7/6/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 7,842 | $236K | 7/6/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 25,000 | $68K | 3/14/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 3,067 | $97K | 3/14/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 2,195 | $71K | 3/14/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 100 | $3K | 3/14/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 16,678 | $506K | 3/14/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 2,960 | $99K | 3/14/2022 | View on chart |
| FATE | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 4,152 | $201K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 418 | $21K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 5,245 | $243K | 1/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 351 | $17K | 1/10/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 25,000 | $68K | 12/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 2,100 | $96K | 12/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 7,018 | $328K | 12/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 6,564 | $313K | 12/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 7,718 | $376K | 12/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 1,600 | $79K | 12/13/2021 | View on chart |
| FATE | ▲ Buy | Grant | 60,958 | $0 | 11/19/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 25,000 | $68K | 9/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 15,809 | $1.0M | 9/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 8,391 | $561K | 9/13/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 800 | $54K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.